Advertisement

Cambridge-based Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY), a company that aims to treat diseases by moderating the genes in living cells, announced that it began a Phase 2 trial of a drug candidate to treat transthyretin-mediated amyloidosis (ATTR), a hereditary disease that can damage the heart and nervous system.

SOURCE

Advertisement
Advertisement